Targeting death receptors in cancer with Apo2L/TRAIL

Current Opinion in Pharmacology

Volumn 4, Issue 4, 2004, Pages 333-339

  Kelley, Sean K ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN 2 LIGAND; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; GAMMA INTERFERON; IRINOTECAN; PROTEIN P53; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; COLON CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SENSITIVITY; GENE INACTIVATION; GLIOMA; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG CANCER; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 3342894130     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.02.006     Document Type: Review

References (51)

1. Ashkenazi A. Dixit V.M. Death receptors: signling and modulation Science 281 1998 1305-1308
2. Ashkenazi A. Targeting death and decoy receptors in the tumour-necrosis factor superfamily Nat Rev Cancer 2 2002 420-430
3. Lawrence D. Shahrokh Z. Marsters S. Achilles K. Shih D. Mounho B. Hillan K. Totpal K. DeForge L. Schow P. et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nat Med 7 2001 383-385
4. Kelley S.K. Harris L.A. Xie D. Deforge L. Totpal K. Bussiere J. Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J Pharmacol Exp Ther 299 2001 31-38
5. Wiley S.R. Schooley K. Smolak P.J. Din W.S. Huang C.P. Nicholl J.K. Sutherland G.R. Davis-Smith T. Rauch C. Smith C.A. Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673-682
6. Pitti R.M. Marsters S.A. Ruppert S. Donahue C.J. Moore A. Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor receptor family J Biol Chem 271 1996 12687-12690
7. Hymowitz S.G. O'Connel M.P. Ultsch M.H. Hurst A. Totpal K. Ashkenazi A. de Vos A.M. Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric rshApo2L/TRAIL Biochemistry 39 2000 633-640
8. Schneider P. Olson D. Tardivel A. Browning B. Lugovskoy A. Gong D. Dobles M. Hertig S. Hofmann K. Van Vlijmen H. et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) J Biol Chem 278 2003 5444-5454
9. LeBlanc H.N. Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors Cell Death Differ 10 2003 66-75
10. Le Blanc H. Lawrence D. Varfolomeev E. Totpal K. Morlan J. Schow P. Fong S. Schwall R. Sinicropi D. Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax Nat Med 8 2002 274-281
11. Deng Y. Lin Y. Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO Genes Dev 16 2002 33-45
12. Ravi R. Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with Sulindac-mediated inhibition of Bcl-xL Cancer Res 62 2002 1583-1587
13. Takeda K. Hayakawa Y. Smyth M.J. Kayagaki N. Yamaguchi N. Kakuta S. Iwakura Y. Yagita H. Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nat Med 7 2001 94-100
14. Cretney E. Takeda K. Yagita H. Glaccum M. Peschon J.J. Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J Immunol 168 2002 1356-1361
15. Smyth M.J. Takeda K. Hayakawa Y. Peschon J.J. van den Brink M.R. Yagita H. Nature's TRAIL-on a path to cancer immunotherapy Immunity 18 2003 1-6
16. Herbeuval J.P. Lambert C. Sabido O. Cottier M. Fournel P. Dy M. Genin C. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis J Natl Cancer Inst 95 2003 611-621
17. Song K. Chen Y. Goke R. Wilmen A. Seidel C. Goke A. Hilliard B. Chen Y. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression J Exp Med 191 2000 1095-1104
18. Hilliard B. Wilmen A. Seidel C. Liu T.S. Goke R. Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis J Immunol 166 2001 1314-1319
19. Lamhamedi-Cherradi S.E. Zheng S.J. Maguschak K.A. Peschon J. Chen Y.H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice Nat Immunol 4 2003 255-260
20. Cretney E. Uldrich A.P. Berzins S.P. Strasser A. Godfrey D.I. Smyth M.J. Normal thymocyte negative selection in TRAIL-deficient mice J Exp Med 198 2003 491-496
21. Almassan A. Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev 14 2003 337-348
22. Kotelkin A. Prikhod'ko E.A. Cohen J.I. Collins P.L. Bukreyev A. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand J Virol 77 2003 9156-9172
23. Mundt B. Kuhnel F. Zender L. Paul Y. Tillmann H. Trautwein C. Manns M.P. Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis FASEB J 17 2003 94-96
24. Tollefson A.E. Toth K. Doronin K. Kuppuswamy M. Doronina O.A. Lichtenstein D.L. Hermiston T.W. Smith C.A. Wold W.S. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins J Virol 75 2001 8875-8887
25. Bodmer J.L. Meier P. Tschopp J. Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL J Biol Chem 275 2000 20632-20637
26. Ashkenazi A. Pai R. Fong S. Leung S. Lawrence D. Marsters S. Blackie C. Chang L. McMurtrey A. Hebert A. et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155-162
27. Pollack I.F. Erff M. Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells Clin Cancer Res 7 2001 1362-1369
28. Qin J.Z. Chaturvedi V. Bonish B. Nickoloff B.J. Avoiding premature apoptosis of normal epidermal cells Nat Med 7 2001 385-386
29. Jo M. Kim T.H. Seol D.W. Esplen J.E. Dorko K. Billiar T.R. Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat Med 6 2000 564-567
30. Gliniak B. Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11 Cancer Res 59 1999 6153-6158
31. Naka T. Sugamura K. Hylander B.L. Widmer M.B. Rustum Y.M. Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice Cancer Res 62 2002 5800-5806
32. Chinnaiyan A.M. Prasad U. Shankar S. Hamstra D.A. Shanaiah M. Chenevert T.L. Ross B.D. Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc Natl Acad Sci USA 97 2000 1754-1759
33. Walczak H. Miller R.E. Ariail K. Gliniak B. Griffith T.S. Kubin M. Chin W. Jones J. Woodward A. Le T. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 1999 157-163
34. Roth W. Isenman S. Naumann U. Kugler S. Bahr M. Dichgans J.A. Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in a thymic mice in the absence of neurotoxicity Biochem Biophys Res Commun 265 1999 479-483
35. Fulda S. Wick W. Weller M. Debatin K.M. Smac agonists sensitize for rshApo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Nat Med 8 2002 808-815
36. Ray S. Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11 Cancer Res 63 2003 4713-4723
37. Mitsiades C.S. Treon S.P. Mitsiades N. Shima Y. Richardson P. Schlossman R. Hideshima T. Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications Blood 98 2001 795-804
38. Shigeno M. Nakao K. Ichikawa T. Suzuki K. Kawakami A. Abiru S. Miyazoe S. Nakagawa Y. Ishikawa H. Hamasaki K. et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation Oncogene 22 2003 1653-1662
39. Arizono Y. Yoshikawa H. Naganuma H. Hamada Y. Nakajima Y. Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents Br J Cancer 88 2003 298-306
40. Bouralexis S. Findlay D.M. Atkins G.J. Labrinidis A. Hay S. Evdokiou A. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy Br J Cancer 89 2003 206-214
41. Miao L. Yi P. Wang Y. Wu M. Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703 Eur J Biochem 270 2003 2721-2731
42. Hotta T. Suzuki H. Nagai S. Yamamoto K. Imakiire A. Takada E. Itoh M. Mizuguchi J. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential J Orthop Res 21 2003 949-957
43. Jones D.T. Ganeshaguru K. Mitchell W.A. Foroni L. Baker R.J. Prentice H.G. Mehta A.B. Wickremasinghe R.G. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand Br J Haematol 121 2003 713-720
44. Xu Z.W. Kleeff J. Friess H. Buchler M.W. Solioz M. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells Anticancer Res 23 2003 251-258
45. Ramp U. Caliskan E. Mahotka C. Krieg A. Heikaus S. Gabbert H.E. Gerharz C.D. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage Br J Cancer 88 2003 1800-1807
46. Totzke G. Schultze-Osthoff K. Jänicke R.U. Cyclooxygenase-2 (cox-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition Oncogene 22 2003 8021-8030
47. Tschopp J. Irmler M. Thome M. Inhibition of Fas death signals by FLIPs Curr Opin Immunol 10 1998 552-558
48. Leverkus M. Walczak H. McLellan A. Fries H.W. Terbeck G. Brocker E.B. Kampgen E. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis Blood 96 2000 2628-2631
49. Salvesen G.S. Caspases and apoptosis Essays Biochem 38 2002 9-19
50. MacFarlane M. Merrison W. Bratton S.B. Cohen G.M. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiqu-itination in vitro J Biol Chem 277 2002 36611-36616
51. Jin H. Yang R. Fong S. Totpal K. Lawrence D. Zheng Z. Ross J. Koeppen H. Schwall R. Ashkenazi A: Apo2L/TRAIL cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004, in press.